North China Pharmaceutical Co., Ltd: The Adenosine Cobamides Capsules has obtained a drug registration certificate.

On July 29th, Huabei Pharmaceutical announced that the company has recently received the "Drug Registration Certificate" for Adenosine Cobalamin Capsules issued by the National Medical Products Administration. This product can inhibit abnormal lipid synthesis of nerve myelin sheath, block the occurrence and development of nerve fiber demyelination; promote protein and lipid synthesis, repair damaged nerves; reduce abnormal TNF levels, inhibit the occurrence of SACD, participate in the tricarboxylic acid cycle, promote the metabolism of three major substances, maintain normal cell function; normalize the content of glutathione, protect nerve cells; participate in hemoglobin synthesis, improve anemia. This product is considered to have passed the evaluation of generic drug quality and efficacy consistency. As of now, the cumulative research and development investment is 10.9382 million RMB.